$2.91
-0.22 (-7.03%)
Open$3.19
Previous Close$3.13
Day High$3.19
Day Low$2.85
52W High$46.78
52W Low$26.60
Volume—
Avg Volume648.1K
Market Cap9.78M
P/E Ratio—
EPS$-0.28
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+1,384.5% upside
Current
$2.91
$2.91
Target
$43.20
$43.20
$28.55
$43.20 avg
$44.32
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 1.69M | 1.69M | 1.36M |
| Net Income | 118.4K | 113.8K | 71.1K |
| Profit Margin | 7.0% | 6.8% | 5.2% |
| EBITDA | 180.1K | 185.2K | 152.7K |
| Free Cash Flow | 113.7K | 84.7K | 88.4K |
| Rev Growth | -7.6% | +15.2% | +21.3% |
| Debt/Equity | 0.66 | 0.76 | 0.92 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |